Westminster, CA – May 19, 2020 – BioLargo, Inc.
(OTCQB:BLGO), developer of sustainable technologies and a full-service
environmental engineering company, today announced that Clyraguard, the product
developed by its partially owned subsidiary Clyra Medical Technologies in
response to the COVID-19 pandemic has been successfully shown to cause complete
inactivation of the SARS-CoV-2 virus in laboratory testing. Testing was done
under the supervision of Dr. Slobodan Paessler, DVM, PhD at the Galveston
National Laboratory at the University of Texas Medical Branch at Galveston.
Clyraguard is a personal protective spray designed to help
prevent cross contamination of the personal protective equipment worn by
front-line healthcare workers by the SARS-CoV-2 coronavirus, the cause of
COVID-19 disease. This clear, colorless and odorless product has been
extensively tested and found to be non-irritating, non-sensitizing, non-toxic,
and non-staining.
More information about this exciting news can be found in
Clyra Medical Technologies’ press release, linked here: http://www.globenewswire.com/news-release/2020/05/19/2035694/0/en/Clyraguard-Shows-Complete-Inactivation-of-SARS-CoV-2-Virus-in-Study-at-Galveston-National-Lab.html.
BioLargo President & CEO Dennis P. Calvert commented,
“We are very proud of the Clyra team for creating this powerful tool to help
fight the spread of SARS-CoV-2. Clyraguard will help protect people as we
continue to fight the spread of the pandemic and will help people get back to living
their lives.”
More information about Clyraguard can be seen at the Clyra
Medical web site, www.clyramedical.com/clyraguard.
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products
and environmental engineering solutions provider driven by a mission to “make
life better”. We feature unique
disruptive solutions to deliver clean air, clean water and a clean, safe
environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne
Clean Industrial Odor Eliminator (www.cupridyne.com),
which eliminates the odor-causing compounds and VOCs rather than masking them,
and is now winning over leading companies in the solid waste handling and
wastewater industries and other industries that contend with malodors and VOCs.
Our subsidiary BioLargo Water (www.biolargowater.ca)
develops the Advanced Oxidation System "AOS," a disruptive industrial
water treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and
licensor to our subsidiary Clyra Medical (www.clyramedical.com),
which features effective and gentle solutions for chronic infected wounds to
promote infection control and regenerative tissue therapy.
About Clyra Medical Technologies, Inc.
Clyra Medical Technologies offers patented and patent
pending effective, and safe advanced antimicrobial products. Clyra has
developed an FDA 510(k)-cleared product offering a Wound Irrigation Solution
for advanced wound care available to hospitals and physicians in the U.S.
In addition, Clyra offers ClyraGuard Personal Protective
Spray, an effective, long-lasting disinfectant for personal protective
equipment.
Clyra products are designed to offer the highest standards
of antimicrobial and antiviral activity that are tissue and skin friendly,
non-staining and are effective against biofilms.
*Data on File
About Galveston National Laboratory/UTMB
The Galveston National Laboratory (GNL) is a sophisticated
high containment research facility that serves as a critically important
resource in the global fight against infectious diseases. The GNL is located on
the campus of the University of Texas Medical Branch and operates under the
umbrella of UTMB’s Institute for Human Infections and Immunity.
The National Institute of Allergy and Infectious Diseases
(NIAID) provides funding for the BSL4 laboratories and operations at the GNL,
and the lab’s top priority is research to develop diagnostics, therapeutics and
vaccines to combat the most dangerous diseases in the world.
Researchers at the GNL are internationally known for their
expertise working with pathogens including Ebola and Marburg, emerging
infectious diseases like MERS, and mosquito borne viruses like Zika and
Chikungunya. The Galveston National Laboratory is home to research that is
funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease
Control & Prevention and other federal agencies, as well as academic
partners, private foundations, and the Biopharmaceutical industry.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release includes “forward-looking
statements” within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. Actual results may
differ from expectations, estimates and projections and, consequently, you
should not rely on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the actual results
to differ materially from the expected results.
No comments:
Post a Comment